نتایج جستجو برای: hemophilic patients
تعداد نتایج: 2085548 فیلتر نتایج به سال:
A long-acting factor VIII (FVIII) as a replacement therapy for hemophilia A would significantly improve treatment options for patients with hemophilia A. To develop a FVIII with an extended circulating half-life, but without a reduction in activity, we have engineered 23 FVIII variants with introduced surface-exposed cysteines to which a polyethylene glycol (PEG) polymer was specifically conjug...
The management of nonunion and limb length discrepancy has remained a constant challenge in hemophilic patients. In this study, we aimed to present the treatment of femur infected nonunion and limb length discrepancy in a twenty-seven-year-old patient with hemophilia type A. A 27-year-old male patient with hemophilia type A referred to our institution for the treatment of right femur infected n...
One of the more puzzling features of modern blood coagulation theory is the pathogenesis of hemophilia with its mutually exclusive "procoagulant-deficit" and "anticephalin-excess" hypotheses. Briefly, in the "procoagulant-defidt" hypothesis the hemophilia gene is expressed biochemically as inadequate production of the antihemophilic factor (AHF), a coagulant factor required for normal hemostasi...
The prevalence, clinical relevance, and risk factors of serum cryoglobulins in hemophilic patients with chronic hepatitis C virus (HCV) infection are unknown. We studied 135 consecutive hemophilic patients (median age, 31 years; range, 10 to 69 years) with chronic hepatitis C, exposed to the virus for 10 to 41 years. A total of 67 patients were coinfected with the human immunodeficiency virus (...
The article titled; Distribution of hepatitis C virus genotypes in Iranian patients with congenital bleeding disorders, revealed the genotype distribution of HCV in Iranian hemophilic patients. 4 In this study, results demonstrate genotype 1a was the most frequent HCV genotype (58%), followed by genotype 3a (18.5%) and genotype 1b (14.7%). Mixed genotypes were also detected in 6.2%. These findi...
The interference of antibodies to factor VIII coagulant protein (Vlll:C) of 9 nonhemophilic patients with the binding to factor VIII coagulant antigen (VIII:CAg) of a reference hemophilic ‘251-Fab’ reagent, used in a liquid phase Vlll:CAg assay, was studied. The binding competition was estimated from immunoradiometric assay (IRMA) doseresponse slope of Vlll:CAg present in patient plasma. interf...
BACKGROUND Hemophilia A is a congenital bleeding disorder caused by defective or deficient factor VIII (FVIII). The active form of FVIII is the co-factor for the serine protease factor IXa (FIXa) in the membrane-bound intrinsic tenase (FVIIIa-FIXa) complex. The assembly of the FVIIIa-FIXa complex on the activated platelet surface is critical for successful blood clotting. OBJECTIVES To charac...
The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocytes relies upon peripheral tolerance mechanisms. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key re...
Qualitative or quantitative defects in the genes for coagulation factors VIII (FVIII) or IX (FIX) result in a life-threatening, bleeding phenotype (hemophilia A (HA) or B (HB), respectively). Although hemophilia treatment by clotting factor replacement is effective, a proportion of patients develop neutralizing antibodies (inhibitors) to the infused factor that complicate the disease management...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید